Yuhan Corp
KRX:000100
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
57 999.9966
163 700
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Yuhan Corp
Yuhan Corp
Cash & Cash Equivalents
Yuhan Corp
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Yuhan Corp
KRX:000100
|
Cash & Cash Equivalents
₩229.7B
|
CAGR 3-Years
5%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
3%
|
|
|
SK Biopharmaceuticals Co Ltd
KRX:326030
|
Cash & Cash Equivalents
₩239.7B
|
CAGR 3-Years
59%
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
|
|
Hanmi Science Co Ltd
KRX:008930
|
Cash & Cash Equivalents
₩50.6B
|
CAGR 3-Years
45%
|
CAGR 5-Years
25%
|
CAGR 10-Years
11%
|
|
|
Hanmi Pharm Co Ltd
KRX:128940
|
Cash & Cash Equivalents
₩47.9B
|
CAGR 3-Years
-35%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-4%
|
|
|
S
|
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
|
Cash & Cash Equivalents
₩134B
|
CAGR 3-Years
28%
|
CAGR 5-Years
17%
|
CAGR 10-Years
14%
|
|
|
C
|
Celltrion Pharm Inc
KOSDAQ:068760
|
Cash & Cash Equivalents
₩28.1B
|
CAGR 3-Years
-23%
|
CAGR 5-Years
66%
|
CAGR 10-Years
28%
|
|
Yuhan Corp
Glance View
Yuhan Corp., a leading player in South Korea's pharmaceutical industry, has a rich history dating back to its founding in 1926. The company has successfully built a strong reputation for innovation and reliability, developing a diverse portfolio that includes prescription drugs, over-the-counter medications, and biopharmaceuticals. Yuhan stands out not only for its robust domestic market presence but also for its strategic global partnerships, which have allowed it to expand its reach and enhance its product offerings. Investors can appreciate Yuhan's focus on research and development, as evidenced by its significant investment in cutting-edge therapies and advanced drug formulations that cater to unmet medical needs. In recent years, Yuhan Corp. has intensified its commitment to growth through collaborations with international companies, enhancing its capabilities in areas such as oncology, autoimmune disorders, and neurology. These partnerships position Yuhan well to capitalize on global market trends and shifting healthcare demands, offering promising avenues for revenue generation. As an investor, one would find comfort in Yuhan's strong financial performance, characterized by steady revenue growth, increasing profitability, and prudent cost management. With a forward-looking vision and a solid foundation, Yuhan Corp. represents a compelling opportunity for those interested in tapping into the thriving pharmaceutical sector and benefiting from innovations that improve healthcare outcomes globally.
See Also
What is Yuhan Corp's Cash & Cash Equivalents?
Cash & Cash Equivalents
229.7B
KRW
Based on the financial report for Sep 30, 2024, Yuhan Corp's Cash & Cash Equivalents amounts to 229.7B KRW.
What is Yuhan Corp's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
3%
Over the last year, the Cash & Cash Equivalents growth was -16%. The average annual Cash & Cash Equivalents growth rates for Yuhan Corp have been 5% over the past three years , -3% over the past five years , and 3% over the past ten years .
You don't have any saved screeners yet
